Delving into the Latest Updates on Chailian Ganmao Granules with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

Acute upper respiratory infectionCommon Cold

Originator Organization

Wuhan Shuanglong Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Wuhan Shuanglong Pharmaceutical Co., Ltd.

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

（1）初步评价柴连感冒颗粒治疗急性上呼吸道感染（风热证）的有效性。（2）探索柴连感冒颗粒治疗急性上呼吸道感染（风热证）的合理剂量，为Ⅱb 期临床研究提供依据。（3）观察柴连感冒颗粒治疗急性上呼吸道感染（风热证）的安全性。

[Translation]

(1) To preliminarily evaluate the effectiveness of Chailian Ganmao Granules in treating acute upper respiratory tract infection (wind-heat syndrome). (2) To explore the reasonable dosage of Chailian Ganmao Granules in treating acute upper respiratory tract infection (wind-heat syndrome) and provide a basis for Phase IIb clinical study. (3) To observe the safety of Chailian Ganmao Granules in treating acute upper respiratory tract infection (wind-heat syndrome).

Start Date27 Mar 2018

Sponsor / Collaborator

Wuhan Shuanglong Pharmaceutical Co., Ltd.

100 Clinical Results associated with Chailian Ganmao Granules

Login to view more data

100 Translational Medicine associated with Chailian Ganmao Granules

Login to view more data

100 Patents (Medical) associated with Chailian Ganmao Granules

Login to view more data

100 Deals associated with Chailian Ganmao Granules

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute upper respiratory infection	Phase 2	CN	Wuhan Shuanglong Pharmaceutical Co., Ltd.	27 Mar 2018
Common Cold	Phase 2	CN	Wuhan Shuanglong Pharmaceutical Co., Ltd.	27 Mar 2018